Loading…
Loading…
CLBT does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CLBT and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CLBT and 80,000+ other tickers.
See exactly how CLBT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CLBT and 80,000+ other tickers.
Cellebrite DI Ltd. delivers specialized digital intelligence solutions crafted for legally authorized investigations. Their comprehensive DI platform enables users to efficiently gather, scrutinize, interpret, and oversee digital information throughout the investigative process. These essential tools are utilized in a wide array of scenarios, including cases involving child exploitation, homicides, counter-terrorism operations, border control, sexual offenses, human trafficking, corporate security incidents, intellectual property theft, and civil litigation. A key offering, the Universal…
Hogan's non-discretionary sale satisfied tax withholding obligations from vesting RSUs. He retains 590,777 shares worth $9.25 million.
The partnership unifies what happens in the sky with what's stored on the drone in a single investigative workflow TYSONS CORNER, Va. and PETAH TIKVA, Israel, July 8, 2026 /PRNewswire/ -- Cellebrite DI Ltd.
Cellebrite (CLBT) remains a buy as fundamentals strengthen, with FedRAMP High achieved and federal demand reaccelerating. Q2 ARR guidance of $510–513M implies 22–23% growth, supporting a narrative of renewed momentum post-federal softness. Platform adoption advances, with Inseyets conversions near 60% and growth products now 14% of ARR, lengthening CLBT's growth runway.
Cellebrite DI Ltd. (CLBT) Discusses AI Technology and Innovation in Tech Talk Transcript
Reduces investigative workloads from weeks to minutes accelerating investigations like never before TYSONS CORNER, Va. and PETAH TIKVA, Israel, June 10, 2026 /PRNewswire/ -- Cellebrite DI Ltd.